



## **PsychoGenics Appoints David A. Lowe, as Chief Scientific Officer and Executive Vice President of Research and Development**

TARRYTOWN, N.Y., August 10, 2009 – PsychoGenics Inc., announced the appointment of David A. Lowe, Ph.D., as Chief Scientific Officer (CSO) and Executive Vice President of Research and Development (EVP, R&D). This appointment reflects the Company's growth and expansion into new areas of Central Nervous System (CNS) drug discovery and clinical development, and its continued commitment to the development of novel proprietary technologies to support internal and partnered drug discovery and translational research.

Dr. Lowe has more than 25 years of experience in pharmaceutical drug discovery and product development and an established track record of generating diverse clinical candidates and he will lead the drug discovery and development efforts at PsychoGenics.

"We are very excited that David has joined PsychoGenics" said Emer Leahy, PhD President and CEO. "David is joining PsychoGenics at an important juncture in our Company's evolution as we expand our drug discovery capabilities and explore interesting mechanisms for clinical development such as spin-off entities. Having known David for several years, I am confident he will add significant value with his tremendous energy and creativity, solid management experience, and his extensive knowledge of CNS R&D and translational research."

Dr. Lowe most recently served as CSO and member of the Board of Directors at Memory Pharmaceuticals, which was acquired by Hoffman-La Roche Inc. Before that, he served as Executive Vice President and Chief Scientific Officer of Fidelity Biosciences and as the President and Chief Executive Officer of EnVivo Pharmaceuticals Inc. Dr. Lowe has held senior Neuroscience R&D positions in three large pharmaceutical companies, including with Sandoz Ltd (now Novartis), Bayer AG, and Roche Bioscience, where he served as the Vice President and Therapeutic Area Head, CNS.

"I am excited to be a part of this innovative and growing organization, especially as it transitions its drug discovery programs into clinical development. I am impressed with the quality of the research and the company's diverse drug discovery technologies." Dr. Lowe said. "I look forward to advancing the clinical development of PsychoGenics' numerous discoveries through partnerships, through interesting corporate structures such as Psylin Neurosciences, and within PsychoGenics itself."

### **About PsychoGenics**

PsychoGenics is a leader in preclinical behavioral neurobiology. The Company applies its behavioral expertise together with advances in robotics, computer vision, and informatics to provide innovative solutions for central nervous system drug discovery. PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions, and not-for-profit research foundations to help discover treatments for such major neurological and psychiatric disorders as: ALS, anxiety, cognitive impairment, depression, Huntingtons Disease, psychosis/schizophrenia, and Spinal Muscular Atrophy (SMA). The Company's in-house discovery efforts have focused on psychiatric indications.

*For more information on PsychoGenics, Inc. visit: [www.psychogenics.com](http://www.psychogenics.com)*